atai closes $50M PIPE; Beckley BPL-003 Phase 2b meets primary endpoint in TRD

ATAI Life Sciences N.V.

PIPE financing of ~$50M at $2.19/share with Apeiron and other investors; expected to close Q3 2025.
Proceeds will extend cash runway into H2 2027, funding general corporate purposes and clinical development.
Beckley Psytech's Phase 2b of BPL-003 in TRD met primary endpoint: 12mg dose showed MADRS reduction of 11.1 vs 5.8 (p=0.0038) at Day 29.
Both 8mg and 12mg doses showed rapid, durable effects from Day 2 through Week 8; 8mg selected for Phase 3.
Strategic combination with Beckley Psytech now expected to proceed to atai shareholder approval after success criteria met.

item 1.01item 3.02item 7.01item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.